The engEx™ Platform
Codiak has built a proprietary platform for engineering exosome therapeutics.
Pipeline
Codiak’s proprietary engEx™ Platform for exosome engineering and manufacturing is enabling the development of potential therapies for diseases with high unmet needs. Using this breakthrough platform, we can produce exosomes that have precise and intentionally chosen properties and make them at industrial quality and scale.
engEx Therapeutic Pipeline
Codiak is developing a pipeline of engEx therapeutic candidates that may have a transformative impact for patients. With initial focus areas in oncology and neurology, we are exploring engineered exosomes in multiple indications, including immune-based diseases and neurodegenerative disorders.
Oncology
Candidate
Discovery
Preclinical
Clinical
exoSTING™
HNSCC & TNBC
Stage: Preclinical
Stage: Preclinical
Phase 1/2 clinical trial anticipated to begin in H1 2020.
Engineered exosome therapeutic candidate overexpressing Codiak’s proprietary scaffold protein PTGFRN and loaded with a proprietary synthetic cyclic dinucleotide (CDN) to selectively target the STING (stimulator of interferon genes) pathway in antigen presenting cells.
exoIL-12™
CTCL; T-cell rich solid tumors
Stage: Preclinical
Stage: Preclinical
Phase 1/2 clinical trial anticipated to begin in H2 2020.
Engineered exosome therapeutic candidate displaying biologically active IL-12 on the surface of the exosome via Codiak’s novel protein scaffold, PTGFRN. exoIL-12 is engineered to facilitate tumor retention and sustained activity.
exoASO-STAT6™
Myeloid rich solid tumors
Stage: Preclinical
Stage: Preclinical
Engineered exosome therapeutic candidate exogenously loaded with an antisense oligonucleotide (ASO) designed to selectively reprogram M2 immunosuppressive macrophages to an M1 pro-inflammatory phenotype by targeting and decreasing the expression of the key immunosuppressive transcription factor STAT6.
exoASO-STAT3
Hematological Malignancies
Stage: Discovery
Stage: Discovery
Engineered exosomes exogenously loaded with an ASO designed to target and decrease the transcription factor STAT3 to overcome resistance to cancer therapies. This program is part of Codiak’s partnership with Jazz Pharmaceuticals.
exoASO-NRAS
Solid Tumors and Hematological Malignancies
Stage: Discovery
Stage: Discovery
Engineered exosomes exogenously loaded with an ASO designed to target and decrease the key oncogenic driver, NRAS, to overcome resistance to standard cancer therapies. This program is part of Codiak’s partnership with Jazz Pharmaceuticals.
Multiple Targets
Solid Tumors
Stage: Discovery
Stage: Discovery
Neurology
Candidate
Discovery
Preclinical
Clinical
exoSTING™
GBM and LMD
Stage: Preclinical
Stage: Preclinical
Multiple Targets
Neuromuscular Disease
Stage: Discovery
Stage: Discovery
Engineered exosomes designed to deliver and functionally release select payloads, such as nucleic acids and gene therapy and gene editing constructs, in neuromuscular indications. This program is part of Codiak's collaboration with Sarepta Therapeutics.
exoASO-Multiple Targets
Neuro-inflammation
Stage: Discovery
Stage: Discovery
Platform Expansion
In addition to our therapeutic pipeline focus areas, we are exploring the potential of engineered exosomes for a variety of additional applications.
Candidate
Research
exoVACC™
Multiple
Stage: Research
Stage: Research
Engineered exosomes that deliver antigens and adjuvants simultaneously to the same antigen presenting cells. The platform allows luminal expression of antigens and surface expression of immune co-stimulatory molecules designed to create a modular vaccination system. Various adjuvants can be incorporated into the exosomes to enhance the immune response against a broad array of antigens.
Codiak is evaluating the utility of exoVACC in SARS-CoV-2 and HIV under a collaboration with the Ragon Institute of MGH, MIT and Harvard and in various tumor models under a collaboration with the Washington University School of Medicine.
exoAAV
Multiple
Stage: Research
Stage: Research
Engineered exosomes containing adeno-associated virus into the exosome lumen may allow for immune-cloaking to facilitate repeat dosing of AAV and gene delivery to selected cell types based upon exosome tropism. Exosome engineering of AAV producer cells provides a novel approach.
